Elusys Therapeutics, Inc.
Matthew M. Seavey is the Vice President of Business Development & Alliance Mgmt. at Elusys Therapeutics, Inc., responsible for managing ANTHIM® sales and partnerships related to CBRN preparedness. With a background in immunology and extensive experience in pharmaceutical and biotech industries, Matthew has held various leadership roles in research, technology acquisition, and preclinical research at companies like NightHawk Biosciences, Inc. and Skunkworx Bio. Matthew's expertise also includes oncology program management, pharmacology project leadership, and cancer immunotherapy research. With a Ph.D. in Immunology and an MBA, Matthew brings a unique blend of scientific knowledge and business acumen to his strategic roles in the biopharmaceutical industry.
This person is not in any teams
Elusys Therapeutics, Inc.
Elusys Therapeutics is dedicated to delivering innovative medical countermeasures that enable fast, effective, and durable protection against infectious agents. Our goal is to accelerate the development and commercialization of novel biodefense solutions, such as our anthrax antitoxin ANTHIM® (obiltoxaximab), for strategic government partners.